Parabilis Medicines Reports Q3 2026 Results, Holds $1.1 Billion in Cash

Parabilis Medicines reported Q3 2026 revenue of $2.1M and a net loss of $44.5M, with $1.1B in cash. R&D expenses rose to $45.6M. The company presented clinical progress for zolucatetide, including a 72.2% response rate in desmoid tumors. It plans a Phase 3 trial in 2027 and collaborations with Revolution Medicines.

Original reporting
Published Nov 12, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Parabilis Medicines Reports Q3 2026 Results, Holds $1.1 Billion in Cash — source image
Decision brief

The 30-second read

$PBLSBearishMed
01

Why it matters

The earnings release highlights a significant net loss and cash burn, but also promising early trial data and FDA alignment for a pivotal Phase 3 study, creating a mixed short‑term/long‑term outlook.

02

Market read

Primary micro‑cap earnings release with new trial data; short‑term downside risk due to loss, but long‑term upside potential from trial progress.

03

What to watch

The $1.1B cash runway through 2030 provides ample funding for upcoming trials, reducing near‑term financing risk.

Relevance 7/10Novelty 7/10Timing: post‑quarter release

Background

Parabilis Medicines (PBLS) filed an 8‑K with Q3 2026 financials and disclosed clinical progress for its lead candidate zolucatetide.

Company-level read

Ticker impact

$PBLSBearishHigh confidence
Context

Parabilis Medicines reported Q3 2026 results with $2.1M revenue, $44.5M net loss and $1.1B cash, plus Phase 1/2 desmoid tumor data and FDA alignment for a Phase 3 trial.

Expected impact

likely pressure as the market prices in the sizable net loss and cash burn

Evidence & confidence

The disclosed loss and cash burn are material for a micro‑cap biotech, outweighing the positive trial readout which is still early‑stage.

Market effects

Biotech sector may see modest interest in Wnt/β‑catenin pathway programs.

Limited to US‑listed biotech investors.

Low; impact confined to niche biotech investors.

Counterpoint

The strong desmoid tumor response could outweigh short‑term loss concerns, prompting a buy on long‑term potential.

Key entities

  • Parabilis Medicines

    Biotech firm developing zolucatetide for Wnt/β‑catenin‑driven tumors.

  • Revolution Medicines

    Partner in a clinical collaboration on zolucatetide.

Related articles

$PBLSMedAI 8/10

Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile

$PBLSMedAI 8/10

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.

$PBLSMedAI 9/10

Parabilis reports phase 1/2 data for desmoid tumor treatment

Parabilis Medicines (PBLS) reported phase 1/2 trial results for zolucatetide, showing a 72.2% response rate in 18 patients and 100% disease control in 46 patients. The company plans to start a phase 3 trial in 2027, with FDA alignment on study design and endpoints. Zolucatetide has Fast Track and Orphan Drug Designations for desmoid tumors.